Published in Am J Pathol on May 01, 1997
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest (2000) 2.45
Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest (2005) 1.61
The role of complement in the early immune response to transplantation. Nat Rev Immunol (2012) 1.26
Adenosine A₂A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg (2011) 1.07
Metabolism of hyperpolarized [1-¹³C]pyruvate in the isolated perfused rat lung - an ischemia study. NMR Biomed (2012) 1.04
Cellular infiltrates and injury evaluation in a rat model of warm pulmonary ischemia-reperfusion. Crit Care (2004) 1.02
The emerging role of neutrophils in thrombosis-the journey of TF through NETs. Front Immunol (2012) 0.98
An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury. Proc Natl Acad Sci U S A (2000) 0.97
Inflammatory response to pulmonary ischemia-reperfusion injury. Surg Today (2006) 0.93
Primary graft dysfunction. Semin Respir Crit Care Med (2013) 0.93
Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. Respir Res (2009) 0.92
Neutrophil sandwiches injure the microcirculation. Nat Med (2009) 0.91
Oxidative Stress and Lung Ischemia-Reperfusion Injury. Oxid Med Cell Longev (2015) 0.91
Carbon monoxide-saturated preservation solution protects lung grafts from ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2008) 0.86
Innate immunity and resistance to tolerogenesis in allotransplantation. Front Immunol (2012) 0.85
Lung injury after in vivo reperfusion: outcome at 27 hours after reperfusion. Anesthesiology (2008) 0.83
Pulmonary inflammation after lung transplantation. Surgery (2009) 0.83
Which pathways trigger the role of complement in ischaemia/reperfusion injury? Front Immunol (2012) 0.83
Pharmacologic strategies for combating the inflammatory response. J Extra Corpor Technol (2007) 0.82
Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation. Transl Res (2012) 0.82
Impact of epoxyeicosatrienoic acids in lung ischemia-reperfusion injury. Microcirculation (2010) 0.80
The innate immune system and transplantation. Cold Spring Harb Perspect Med (2013) 0.79
Ischaemia-reperfusion injury in orthotopic mouse lung transplants - a scanning electron microscopy study. Int J Exp Pathol (2011) 0.79
Ischemia of the lung causes extensive long-term pulmonary injury: an experimental study. Respir Res (2008) 0.78
Evaluation of early macrophage activation and NF-kappaB activity in pulmonary injury caused by deep hypothermia circulatory arrest: an experimental study. Pediatr Cardiol (2009) 0.77
The Perioperative Lung Transplant Virome: Torque Teno Viruses are Elevated in Donor Lungs and Show Divergent Dynamics In Primary Graft Dysfunction. Am J Transplant (2016) 0.76
Variable Ventilation Improved Respiratory System Mechanics and Ameliorated Pulmonary Damage in a Rat Model of Lung Ischemia-Reperfusion. Front Physiol (2017) 0.75
Diffuse alveolar damage associated with pulmonary thromboembolism. Respir Med Case Rep (2013) 0.75
Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A (1990) 16.34
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med (1985) 11.68
Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol (1982) 10.99
Stimulation of neutrophils by tumor necrosis factor. J Immunol (1986) 5.72
Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest (1977) 4.08
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest (1990) 3.39
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature (1993) 2.38
Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood (1991) 2.10
Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor. J Exp Med (1984) 2.00
Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons. J Clin Invest (1984) 2.00
Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol (1992) 1.84
Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukoc Biol (1987) 1.81
Interferons as macrophage-activating factors. III. Preferential effects of interferon-gamma on the interleukin 1 secretory potential of fresh or aged human monocytes. J Immunol (1985) 1.65
Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest (1978) 1.44
Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation (1988) 1.39
Quantitation and kinetics of blood monocyte migration to acute inflammatory reactions, and IL-1 alpha, tumor necrosis factor-alpha, and IFN-gamma. J Immunol (1993) 1.38
Neutrophil and nonneutrophil-mediated injury in intestinal ischemia-reperfusion. Ann Surg (1993) 1.34
Priming the macrophage respiratory burst with IL-4: enhancement with TNF-alpha but inhibition by IFN-gamma. Immunology (1990) 1.31
Evidence for tumor necrosis factor-induced pulmonary microvascular injury after intestinal ischemia-reperfusion injury. Ann Surg (1990) 1.29
Pure interferon gamma enhances class II HLA antigens on human monocyte cell lines. Eur J Immunol (1984) 1.28
Pattern of injury and the role of neutrophils in reperfusion injury of rat lung. J Surg Res (1995) 1.23
Complement activation and neutropenia occurring during cardiopulmonary bypass. J Thorac Cardiovasc Surg (1981) 1.21
Evidence for neutrophil-related acute lung injury after intestinal ischemia-reperfusion. Surgery (1989) 1.17
Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion. Ann Surg (1992) 1.13
Potential role of monocyte chemoattractant protein 1/JE in monocyte/macrophage-dependent IgA immune complex alveolitis in the rat. J Immunol (1992) 1.12
Requirements for neutrophil products and L-arginine in ischemia-reperfusion injury. Am J Pathol (1993) 1.12
Cytokine-induced IL-1 beta gene expression in the human polymorphonuclear leukocyte: transcriptional and post-transcriptional regulation by tumor necrosis factor and IL-1. J Immunol (1991) 1.05
Systemic complement activation and acute lung injury. Fed Proc (1986) 1.03
Interleukin-1 secretion by human alveolar macrophages stimulated with endotoxin is augmented by recombinant immune (gamma) interferon. Am Rev Respir Dis (1986) 1.01
Endotoxin-induced cytokine gene expression in vivo. IV. Expression of interleukin-1 alpha/beta and interleukin-1 receptor antagonist mRNA during endotoxemia and during endotoxin-initiated local acute inflammation. Am J Pathol (1992) 1.00
Tumor necrosis factor enhances the neutrophil-dependent increase in endothelial permeability. J Cell Physiol (1990) 1.00
The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion. Transplantation (1990) 1.00
The effect of tumor necrosis factor-alpha and interferon-gamma on neutrophil function. J Surg Res (1989) 0.90
Interleukin-6, a marker of preservation injury in clinical lung transplantation. J Heart Lung Transplant (1993) 0.90
Pulmonary edema after pulmonary artery occlusion and reperfusion. Am Rev Respir Dis (1989) 0.89
Effect of in vivo TNF administration on superoxide production and PKC activity of rat alveolar macrophages. Am J Physiol (1993) 0.85
Disparate effects of nitric oxide on lung ischemia-reperfusion injury. Ann Thorac Surg (1995) 0.83
Involvement of complement in B-cell, T-cell and monocyte/macrophage activation. Immunol Lett (1987) 0.83
Effect of prostaglandin I2 and superoxide dismutase on reperfusion injury of warm ischemic lung. Ann Thorac Surg (1992) 0.79
Release of tumor necrosis factor after pulmonary artery occlusion and reperfusion. Am Rev Respir Dis (1993) 0.79
Modulation of alveolar macrophage leukotriene B4 released by complement component C5. J Lab Clin Med (1990) 0.78
Acute inflammation in a sheep model of unilateral lung ischemia: the role of interleukin-8 recruitment of polymorphonuclear leukocytes. Am J Respir Cell Mol Biol (1993) 0.77
The role of complement in the function of the monocyte - macrophage system. Haematol Blood Transfus (1981) 0.77
The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA (2000) 12.26
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science (1989) 4.99
A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med (1967) 4.94
The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med (1968) 4.79
A neutrophil chemotactic factor from human C'5. J Immunol (1969) 4.46
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med (1967) 3.87
Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med (1997) 3.85
C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol (1970) 3.75
Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun (1988) 3.63
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
Acute immunologic pulmonary alveolitis. J Clin Invest (1974) 3.53
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem (1984) 3.32
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med (1967) 3.15
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Chemotoxis of mononuclear cells. J Exp Med (1968) 2.95
Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science (1993) 2.71
The chemosuppression of chemotaxis. J Exp Med (1966) 2.62
Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med (1993) 2.62
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest (1983) 2.52
Protective effects of C5a blockade in sepsis. Nat Med (1999) 2.50
Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest (1991) 2.50
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Role of oxygen metabolites in immune complex injury of lung. J Immunol (1981) 2.39
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol (1977) 2.26
Evidence for soluble immune complexes in the pathogenesis of the glomerulonephritis of quartan malaria. Lancet (1969) 2.22
Cardiac transplantation with cyclosporin A and prednisone. Ann Surg (1982) 2.21
C3 leukotactic factors produced by a tissue protease. J Exp Med (1969) 2.19
Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol (1992) 2.18
Human herpesvirus 6 in salivary glands. Lancet (1990) 2.15
Biochemical demonstration of the activatable esterase of the rabbit netrophil involved in the chemotactic response. J Immunol (1970) 2.12
In vivo damage of rat lungs by oxygen metabolites. J Clin Invest (1981) 2.10
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Pulmonary endothelial cell killing by human neutrophils. Possible involvement of hydroxyl radical. Lab Invest (1985) 2.01
Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol (1979) 1.96
Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol (1996) 1.95
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93
Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes. Am J Pathol (1978) 1.91
Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med (1967) 1.90
Leukotactic factors elaborated by virus-infected tissues. J Exp Med (1972) 1.89
Neutropenia induced by systemic infusion of chemotactic factors. J Immunol (1977) 1.89
Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology (1989) 1.88
Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med (1974) 1.88
Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest (1989) 1.86
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Impaired leucotactic responsiveness in a child with recurrent infections. Lancet (1969) 1.78
Selective neutrophil desensitization to chemotactic factors. J Cell Biol (1979) 1.77
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol (1993) 1.74
Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg (1998) 1.71
Leukotactic factors in health and disease. Am J Pathol (1971) 1.71
Impaired neutrophil chemotaxis in patients with juvenile and rapidly progressing periodontitis. J Periodontal Res (1979) 1.70
Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody. J Immunol (1993) 1.68
Neutrophil chemotactic factors and related clinical disorders. Arthritis Rheum (1970) 1.68
Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. J Biol Chem (2000) 1.66
Lung and dermal vascular injury produced by preformed immune complexes. Am Rev Respir Dis (1978) 1.64
Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis (1984) 1.64
C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest (1979) 1.63
Isolation from human serum of an inactivator of bacterial lipopolysaccharide. Am J Pathol (1977) 1.58
Influence of inhibitors of cellular function on chemotactic factor-induced neutrophil aggregation. J Immunol (1977) 1.57
Two distinct chemotactic factor inactivators in human serum. J Immunol (1975) 1.55
Inhibition of in vivo and in vitro neutrophil responses to chemotactic factors by a competitive antagonist. J Immunol (1978) 1.55
Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol (1989) 1.55
Chemotaxis of human eosinophils. Am J Pathol (1969) 1.54
Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 1.53
Chemotaxis of rat lymphocytes. J Immunol (1977) 1.53
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol (1995) 1.53
Ulcerlike lesions of the aorta: imaging features and natural history. Radiology (2001) 1.52
Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (1995) 1.52
Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. J Immunol (1972) 1.51
Surgical delay for acute type A dissection with malperfusion. Ann Thorac Surg (1997) 1.50
Leukotactic dystunction in sarcoidosis. Ann Intern Med (1976) 1.50
Suppression by superoxide dismutase of immune-complex--induced pulmonary alveolitis and dermal inflammation. Am J Pathol (1981) 1.50
Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J (1989) 1.49
Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest (1993) 1.49
Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest (2000) 1.49
Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol (1997) 1.49
Wound complications and treatment of the infected implantable cardioverter defibrillator generator. J Card Surg (1993) 1.48
Chemoattractants of leukocytes, with special reference to lymphocytes. Fed Proc (1972) 1.48
The dissected aorta: percutaneous treatment of ischemic complications--principles and results. J Vasc Interv Radiol (1997) 1.48
Biochemical quantitation of the chemotactic factor inactivator activity in human serum. J Lab Clin Med (1979) 1.46
In vitro and in vivo stimulation of rat neutrophils and alveolar macrophages by immune complexes. Production of O-2 and H2O2. Am J Pathol (1983) 1.46
Congenital 21-hydroxylase deficiency as a new deletion mutation. Detection in a proband during subsequent prenatal diagnosis by HLA typing and DNA analysis. Hum Immunol (1992) 1.45
In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha. J Immunol (1999) 1.45
Aortic cobwebs: an anatomic marker identifying the false lumen in aortic dissection--imaging and pathologic correlation. Radiology (1994) 1.44
Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature (1993) 1.43